Presentation Information
[SY-73-02]Diagnosis and Treatment of Adult Developmental Disorders: A Study Using autism diagnostic observation schedule, second edition
*Dan Nakamura, Kenji Sanada, Akira Iwanami (Department of Psychiatry, Showa University School of Medicine (Japan))
Keywords:
Autism Spectrum Disorder,Attention Deficit Hyperactivity Disorder,Autism Diagnostic Observation Schedule,Second Edition,Gaze measurement,Guanfacine
In this symposium, we will report on some studies on the diagnosis and treatment of developmental disorders in adulthood conducted at Showa University Karasuyama Hospital.
Although ASD and ADHD have been considered to be different developmental disorders, there are many overlapping symptoms, and the relationship between the two disorders remains unclear. So we compared ASD symptoms in adults with 50 ASD, 69 ADHD, and 31 neurotypical controls using the ADOS-2. As a result, it was revealed that there was a high degree of similarity in clinical symptoms between the two groups.
There are also many similarities between the symptoms of ASD and schizophrenia, and the similarity in their symptoms often makes differential diagnosis difficult. We conducted the ADOS-2 on 40 schizophrenia and 50 ASD, and compared the results between the two groups to identify similarities and differences in the symptoms of the two groups.
Furthermore, with the aim of establishing biological markers for the diagnosis of developmental disorders, we conducted eye gaze measurement in human motion scenes of two movies in adults with 22 ADHD and 26 normal subjects, and concluded that the eye movement patterns in ADHD were more similar to those of healthy controls than those of ASD.
Regarding pharmacological treatment, Guanfacine extended-release (GXR) has emerged as a promising alternative to stimulant for the pharmacological treatment of ADHD. GXR is approved globally for treating ADHD in children and adolescents and was first authorized for adult ADHD in Japan in 2019. Since many countries and regions approve GXR only for pediatric ADHD, research on its efficacy in adults has rarely been conducted. We conducted a retrospective medical chart review in adults with ADHD who attended an ADHD specialty clinic at Showa University Karasuyama Hospital, and evaluated clinical outcomes in adults with ADHD treated with GXR in routine clinical practice.
Although ASD and ADHD have been considered to be different developmental disorders, there are many overlapping symptoms, and the relationship between the two disorders remains unclear. So we compared ASD symptoms in adults with 50 ASD, 69 ADHD, and 31 neurotypical controls using the ADOS-2. As a result, it was revealed that there was a high degree of similarity in clinical symptoms between the two groups.
There are also many similarities between the symptoms of ASD and schizophrenia, and the similarity in their symptoms often makes differential diagnosis difficult. We conducted the ADOS-2 on 40 schizophrenia and 50 ASD, and compared the results between the two groups to identify similarities and differences in the symptoms of the two groups.
Furthermore, with the aim of establishing biological markers for the diagnosis of developmental disorders, we conducted eye gaze measurement in human motion scenes of two movies in adults with 22 ADHD and 26 normal subjects, and concluded that the eye movement patterns in ADHD were more similar to those of healthy controls than those of ASD.
Regarding pharmacological treatment, Guanfacine extended-release (GXR) has emerged as a promising alternative to stimulant for the pharmacological treatment of ADHD. GXR is approved globally for treating ADHD in children and adolescents and was first authorized for adult ADHD in Japan in 2019. Since many countries and regions approve GXR only for pediatric ADHD, research on its efficacy in adults has rarely been conducted. We conducted a retrospective medical chart review in adults with ADHD who attended an ADHD specialty clinic at Showa University Karasuyama Hospital, and evaluated clinical outcomes in adults with ADHD treated with GXR in routine clinical practice.